Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
A deal with Jacobio is worth $100m up front.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
New draft guidance could see the agency getting ever stricter.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Interius, one of the most advanced players, will cost $350m.
Posters and mini-orals include another VEGF bispecific.
